Palforzia (Level 3) (peanut allergen powder-dnfp)
Allergenic Extract-Peanut Oral Capsule, Sprinkle
Last reviewed · Source: First Databank (FDB) drug data
Overview
USES: This medication is used by people with peanut allergy to reduce the severity of an allergic reaction when accidentally exposed to peanuts. People using this medication should continue to avoid eating peanuts. This medication is made from peanuts.
It works by making your body less sensitive to small amounts of peanuts. This medication must be used regularly to be effective. It does not work right away to treat an allergic reaction to peanuts.
Generic name: peanut allergen powder-dnfp
Pronunciation: (PEE-nut)
Drug class: Allergenic Extract-Peanut
Therapeutic class: Biologicals
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Palforzia (Level 3)
Indications
The following indications are listed for Palforzia (Level 3):
- Peanut Allergy
Also known as: Allergy To Peanuts.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Palforzia 12 Mg (Level 3) | Maintenance | Take by oral route once daily per package directions. |
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Allergen Immunotherapy/Beta-Blockers
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Beta-blockers may mask early signs and symptoms of anaphylaxis, make the treatment of anaphylaxis more difficult, and increase the severity of the reaction.
CLINICAL EFFECTS: Beta-blockers may reduce a patient's ability to survive a systemic allergic reaction to allergen immunotherapy. Signs and symptoms of anaphylaxis may be masked.
PREDISPOSING FACTORS: Concurrent use of epinephrine with beta-blockers may result in hypertension with reflex bradycardia. Epinephrine resistance in patients with anaphylaxis has been reported.
PATIENT MANAGEMENT: Avoid concomitant administration of immunotherapy and beta-blockers if possible. If patients cannot safely discontinue beta-blockers but have a history of moderate to severe sting-induced anaphylaxis, venom immunotherapy is indicated because the risk of anaphylaxis related to a venom sting is greater than the risk of an immunotherapy-related systemic reaction. In patients taking beta-blockers for whom an acceptable alternative is not available, withholding allergen immunotherapy may be the best option. If both drugs are administered, monitor closely for signs and symptoms of anaphylaxis. Use caution when treating anaphylaxis with epinephrine since response may be poor. Epinephrine administration may worsen anaphylaxis because beta-blockers block the beta effects of epinephrine, which results in predomination of alpha effects. The plasma clearance of epinephrine is decreased. Glucagon may help in the treatment of refractory anaphylaxis in patients receiving beta-blockers.
DISCUSSION: In a case report, a patient taking propranolol was administered pollen extract immunotherapy and immediately developed anaphylaxis. Treatment with epinephrine did not improve symptoms and patient was subsequently intubated.(2) In another case report, a patient taking propranolol was given pollen immunotherapy and developed anaphylaxis. Difficulty in maintaining an adequate blood pressure and pulse continued for several hours despite epinephrine and other supportive measures.(3) There are other case reports of patients taking propranolol with venom immunotherapy that were refractory to treatment.(6-7)
Moderate Interaction: Assess the risk to the patient and take action as needed.
Allergen Immunotherapy/Ustekinumab
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Ustekinumab may decrease the protective effect of allergen immunotherapy.
CLINICAL EFFECTS: Ustekinumab may increase the risk of an allergic reaction to allergen immunotherapy.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Exercise caution in patients receiving or who have received allergen immunotherapy. Counsel patients on the possible increased risk of an allergic reaction.(1)
DISCUSSION: Concurrent use of ustekinumab and allergen immunotherapy has not been evaluated.(1)
Contraindications
There is no enhanced messaging for this drug.
- Eosinophilic esophagitis
- Asthma
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
More Frequent
- Anaphylaxis
- Throat constriction
Less Frequent
- Eosinophilic esophagitis
More Frequent
- Acute abdominal pain
- Cough
- Dyspnea
- Ear itching
- Nausea
- Oral paresthesia
- Oral pruritus
- Pharyngitis
- Pruritus of skin
- Rhinorrhea
- Sneezing
- Urticaria
- Vomiting
- Wheezing
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Peanut allergy | ||
| Z91.010 | ICD10CM | Allergy to peanuts |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.